Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent mRNA hemagglutinin influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The trivalent mRNA hemagglutinin (TIV mRNA-HA) influenza vaccine is an investigational messenger RNA-based vaccine designed to protect against three strains of the influenza virus by encoding the viral hemagglutinin (HA) antigen. The mechanism of action involves delivery of synthetic nucleoside-modified or unmodified mRNA encoding HA antigens via lipid nanoparticles or polymeric nanoparticles, leading to in vivo expression of HA proteins and induction of a protective immune response. This approach aims to elicit robust neutralizing antibody titers and cellular immunity against multiple influenza subtypes. The primary indication is prevention of seasonal or pandemic influenza infection in adults[1][2][5]. Developers include major pharmaceutical companies with expertise in RNA technology.
- Other names
- TIV mRNA-HAtrivalent influenza mRNA-HA vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on trivalent mRNA hemagglutinin influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent mRNA hemagglutinin influenza vaccine.